Two simple gene tests named most brain tumors
Original title: A practical targeted molecular workflow resolves the World Health Organization 2021 integrated diagnosis of diffuse gliomas.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This looked back at tests already done on people, not a new treatment.
The short version
Two common gene tests were enough to fully name most of these brain tumors.
What was studied. Doctors looked back at 307 brain tumors called diffuse gliomas. Each one got two common gene tests, plus a review by 2 tumor doctors.
What they found. The tests gave a full diagnosis in 288 of 307 tumors (93.8%). Only 19 cases (6.2%) were left unsolved. The gene results changed the first diagnosis in 60 tumors (19.5%).
What this means, and what it doesn't
What it could mean: Naming a tumor may not need a big, costly gene panel: One lab test that checks many genes at the same time. It is run on your tumor tissue, not on you. It is one of the tests that takes weeks rather than days. See the glossary. Two simpler tests may be enough. A clear name helps your team pick the right care.
What it doesn't mean: This is not a treatment, and it is not a cure. It was a look back at old records, not a trial. Some tumors, 19 of them here, still needed more testing. It does not promise that your own lab works this way.
Source: PubMed, October 30, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.